DOCSLIB.ORG

Pfizer, Inc., Letter of Support for Parent

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pfizer, Inc., Letter of Support for Parent Ptizer Inc 235 East 42nd Street New York, NY 1OOl7-5755 March 25,2008 Steven Reynolds Director U.S.Nuclear Regulatory Commission Division of Nuclear Material Safety 2443 Warrenville Road, STE 2 10 Lisle, IL 60532-4352 -Re: Parent Company Guarantee for Pharmacia & Upjohn Co. (Kalamazoo, MI) Dear Mr. Reynolds: I am the Chief Executive Officer of Pfizer Inc. located at 235 East 42ndStreet in New York, NY 10017. This letter is in support of this firm's use of the financial test to demonstrate financial assurance, as specified in 10 CFR Part 30. I hereby certify that Pfizer Inc. is currently a going concern, and that it possesses positive tangible net worth in the amount of $23,129,000,000. This firm is required to file a Form 10K with the U.S. Securities and Exchange Commission for the latest fiscal year. The fiscal year of this firm ends on December 3 1. I hereby certify that the content of this letter is true and correct to the best of my knowledge. ofthe ~oard Chief Executive Officer RECEIVED MAR 2 8 2008 .' . Pfizer Inr 235 East 42nd Street New lork. NY 10007-5755 March 25, 2008 Steven Reynolds Director U .S . N uc I ear Reg u la t ory C om m i ss i on Division of Nuclear Material Safet) 2443 Warrenville Road, STE 2 IO Lisle, IL 60532-4352 -Re: Financial Assurance for Pharmacia & Upjohn Company LLC (Kalainazoo, MI) Dear Mr. Reynolds: 1 am the chief financial officer of Pfizer Inc.. 235 East 42'IdStreet, New York. Ne\\ Yorh 1001 7. a corporation. This letter is in support ofthis firm's use of the parent coinpan\ guarantee financial test to demonstrate financial assurance, as specified in IO CFR Part 30. This firm guarantees, through the parent company guarantee submitted to demonstrate compliance under 10 CFR Part 30, the decoinmissioning of the following facilities owned or operated bq this firm. The current cost estimates or certified amounts for decommissioning, so guaranteed, are show for each fac i 1 i ty : Certified Amount or Name of Facility Location of Facility Current Cost Estimates Pliarmacia & Upjohn 7000 Portage Road, $17.133.000 Company LLC Kalamazoo, MI 4900 1 License #2 1-00 182-03 I hereby certify that Pfizer Inc. is currently a going concern, and that it possesses p0sitiL.e tangible net worth in the amount of $23,129,000,000. The fiscal year ofthis firm ends on December 3 1. The figures for the foIIo\~ingitems niarhed \vith a11 asterisk are derived from this firm's independently audited, year-end fliiancial statements and footnotes for the latest completed fiscal year ended December 3 I, 2007, or from the firm's internal accounting records underlying such financial statement. A copy of this firm's most recent financial statements is enclosed. This firm is required to file a Form IO-K with the U.S. Securities and Exchange Commission for the latest fiscal year. This firm has at least one class of equity securities registered under the Securities Exchange Act of 1934. Alternative 2 1 Current decommissioning cost estimates or certified amounts: a. Decommissioning amounts covered by this parent $17,133,000 compaiiy guarantee b. All decommissioning amounts covered by other $3,987.1 38 NRC or Agreement State parent company guarantees or self-guarantees. c. All amounts covered bl parent company guarantees, $l35,7 13,646 self-guarantees, or financial tests of other Federal or State agencies (e.g., EPA) TOTAL $I 56,833,784 2. Current bond rating of most recent unsecured issuance of Rating: Name of Rating this firm. Senrice A AA/Aa 1 Standard & Poor's and Moody's 3. Date of issuance of bond 05/14/07 & 12/13/07 4. Date of maturity of bond 05/15/17 & 12/15/14 *5. Tangible net worth (If any portion of estimates for $23,129,000,000 decommissioning is included in total liabilities on your firm's financial statements, you may add the amount of that portion to this line.) *6. Total assets' in United States (required only if less than $29.5 12.000,000 90 percent of firm's assets are located in the United States) YES NO 7. Is line 5 at least 10 times line I? X *8. Are at least 90 percent of firm's assets located in the United States? If not. X complete line 9. 9. Is line 6 at least IO times line I? X IO. Is the rating specified on line 2 "A" or better X 1 I. Does the licensee have at least one class of equity securities registered X under the Securities Exchange Act of 1934? I Represents identifiable assets only which includes net accounts &r notes receivable. inventories, net fixed assets, goodwill, and net intangibles. 2 I hereby certify that the content of this letter is true and correct to the best of my knowledge. Effective Date: March 25, 2008 Pfizer Inc. Fa7 J'c2L-h Frank A. D'Amelio Senior Vice President and Chief Financial Officer Signature of witness or notary: @M& cc: Dee L. Clernent (Kalarnazoo, MI) 3 KPMG LLP Telephone 212 758 9700 345 Park Avenue Fax 212 758 9819 NewYork. NY 10154 Internet www.us kpmg corn Independent Accountants’ Special Report on Confirmation of Letter from Chief Financial Officer The Board of Directors and Management of Pfizer Inc.: We have audited the consolidated financial statements of Pfizer Inc. (“the Company”) for the year ended December 3 I, 2007, and have issued our report thereon dated February 29,2008. Our work did not extend from the period of February 29,2008 through the date herein. We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. As audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. The Company acquired Pharmacia Corporation on April 16, 2003. Pharmacia & Upjohn Company is a subsidiary of Pharmacia Corporation. Pfizer Inc has prepared documents to demonstrate its financial responsibility under the United States Nuclear Regulatory Commission’s (“NRC”) financial assurance regulations, 10 CFR Part 30. This letter is furnished to assist the following licensee in complying with these regulations and should not be used for other purposes: Pharmacia & Upjohn Company 7000 Portage Road Kalamazoo, MI 4900 1 License Nos.: 2 1-001 82-03 We have performed the procedures enumerated below, which were agreed to by management of Pfizer Inc., solely to assist management of the Company in complying with the NRC - Division of Waste Management financial assurance regulations, Title 10, Chapter 1 of the Code of Federal Regulations, part 30 (“10 CFR part 30”) Appendix C, Criteria Relating to the Use of Financial Tests and Self Guarantees for Providing Reasonable Assurance of Funds for Decommissioning, as of and for the year ended December 3 1,2007. Management of the Company is responsible for Pfizer Inc.’s compliance with those requirements. This agreed-upon procedures engagement was conducted in accordance with attestation standards established by the American Institute of Certified Public Accountants. The sufficiency of these procedures is solely the responsibility of management of the Company. Consequently, we make no representations regarding the KPMG LLP a U S limited liability pannership IS the U S member firm of KPMG Internatmnal. a Swiss cmperatlve sufficiency of the procedures described below either for the purpose for which this report has been requested or for any other purpose. The attached schedule, which was prepared by management of the Company, reconciles the specified financial information furnished in the Company Chief Financial Officer’s (“CFO’s”) letter in response to the regulations with the Company’s audited financial statements (“the Letter”) as of and for the year ended December 3 1,2007. In connection therewith, we have: 1. Compared the amounts in the column “Per Financial Statements” to the amounts contained in the Company’s audited financial statements for the year ended December 3 I, 2007 and found them to be in agreement; 2. Compared the amounts in the column “Per CFO’s Letter” to the amounts set forth in the Letter prepared in response to the NRC’s request and found them to be in agreement; 3. Compared the amounts in the column “Reconciling Items” to the amounts in the Company’s Computron general ledger as of and for the year ended December 3 1,2007 and found them to be in agreement; and 4. Recomputed the mathematical accuracy of the totals set forth in the attached schedule. We were not engaged to, and did not, conduct an examination, the objective of which would be the expression of an opinion on the specified amounts in the Letter. Accordingly, we do not express such an opinion. Had we performed additional procedures, other matters might have come to our attention that would have been reported to you. This report is intended solely for the information and use of the Board of Directors and management of Pfizer Inc., and is not intended to be and should not be used by anyone other than the Board of Directors and management of Pfizer Inc. March 25,2008 PFIZER INC. Year Ended December 3 I, 2007 Dollar amounts in millions Schedule of Reconciling Amounts Contained in Chief Financial Officer’s Letter with Amounts in Financial Statements Per Line Number Per Financial Reconciling CFO’s in CFO’s Letter Statements Items Letter 5 Total Shareholder’s Equity $65,009 Less: Goodw i I I ($21,382) Less: Identifiable intangible assets, less accuin u I ated aiiiort izatio ri ($20,498) Accrued decommissioning costs included in current liabilities Tangible Net Worth $23,129 6 Total Assets $I 15,268 Less: Assets held outside the U.S.
Load more

Recommended publications
  • Pfizer Inr 235 East 42Nd Street New York
    Pfizer Inr 235 East 42nd Street New York. !W 10007-5755 March 25,2008 Steven Reynolds Director U.S. Nuclear Regulatory Commission Division of Nuclear Materials Safety 2443 Warrenville Road, STE 210 Lisle, IL 60532-4352 -Re: Parent Company Guarantee for Pharmacia Corporation (Chesterfield, MO and St. Louis, MO) Dear Mr. Reynolds: I am the Chief Executive Officer of Pfizer Inc. located at 235 East 42"d Street in New York, NY 10017. This letter is in support of this firm's use of the financial test to demonstrate financial assurance, as specified in 10 CFR Part 30. I hereby certify that Pfizer Inc. is currently a going concern, and that it possesses positive tangible net worth in the amount of $23,129,000,000. This firm is required to file a Form 10K with the U.S. Securities and Exchange Commission for the latest fiscal year. The fiscal year of this firm ends on December 3 1. I hereby certify that the content of this letter is true and correct to the best of my knowledge. panof the Board C ief Executive Officer Pfizer lnr 235 East 42nd Street New York, NY 10007-5755 March 25. 2008 Steven Reynolds Director U.S. Nuclear Regulatory Coinmission Division of Nuclear Material Safet) 2443 Warrenville Road STE 2 IO Lisle. IL 60532-4352 -Re: Financial Assurance Demonstration for Pharmacia Corporation (Chesterfield, MO and St. Louis, MO) Dear Mr. Reynolds: I am the chief financial officer of Pfizer Inc., 235 East 42'ld Street, New York. New York 10017, a corporation. This letter is in support of this firm's use of the parent company guarantee financial test to demonstrate financial assurance, as specified in IO CFR Part 30.
    [Show full text]
  • Research and Development at the University of Maryland Baltimore
    RESEARCH AND DEVELOPMENT AT THE UNIVERSITY OF MARYLAND BALTIMORE FISCAL YEAR 2002 ANNUAL REPORT ANNUAL REPORT TABLE OF CONTENTS Overview 1 Extramural Funding at UMB 1 Office of Research and Development Outcomes 2 Success by School 6 Areas of Strength 13 Technology Commercialization 14 New Initiatives 19 Appendixes 20 David J. Ramsay, DM, DPhil President James L. Hughes Vice President, Research & Development www.ord.umaryland.edu RESEARCH AND DEVELOPMENT AT THE UNIVERSITY OF MARYLAND BALTIMORE ANNUAL REPORT FY 02 RESEARCH AND DEVELOPMENT AT THE UNIVERSITY OF MARYLAND BALTIMORE FISCAL YEAR 2002 ANNUAL REPORT OVERVIEW The University of Maryland Baltimore reached a milestone number in extramural funding in FY 02: $305.3 million. The research conducted on campus and the hundreds of projects funded from federal, state and local governments and the private sector demonstrate UMB’s ever-increasing contribution to the life sciences and health care research fields. As an economic engine for Maryland, UMB provides access to millions of dollars of research to the business community. The commercial potential for much of this work is being actively patented and licensed. Summary of Success Principal Investigators with Awards: 617 Principal Investigators with $1 million Plus in Awards: 44 Funding Applications: 2,274 Funding Awards: 1,673 Total Dollar Amount of Extramural Funding: $305.3 Million Total Dollar Amount of Extramural Funding through ORD: $250 Million % of Total Extramural Funding: 82% Volume of Federal Awards: $142.7 Million NIH Funding Amount: $127.2 Million % of Indirect Costs: 22.8% EXTRAMURAL FUNDING AT UMB Support for extramural funding at the UMB campus has tripled in the last eight years.
    [Show full text]
  • 2014.10.22-110Cv00528-Pfizer-Etal
    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC., PHARMACIA & UPJOHN ) COMPANY, PHARMACIA & UP JOHN ) COMPANY LLC, SUGEN, INC., C.P .. ) PHARMACEUTICALS INTERNATIONAL ) C.V., PFIZER PHARMACEUTICALS LLC, ) C.A. No. 10-528-GMS and PF PRISM C.V., ) ) Plaintiffs, ) ) v. ) ) MYLAN PHARMACEUTICALS INC., ) ) Defendant. ) _______________________________ ) MEMORANDUM I. INTRODUCTION In this patent infringement action, plaintiffs Pfizer Inc., Pharmacia & Upjohn Company, Pharmacia & Upjohn Company LLC, Sugen, Inc., C.P. Pharmaceuticals International C.V., Pfizer Pharmaceuticals LLC, and PF Prism C.V. (collectively, "Pfizer") allege that pharmaceutical products proposed by defendant Mylan Pharmaceuticals Inc. ("Mylan") infringe the asserted claims of the patents-in-suit. (D.I. 1.) The court held a four-day bench trial in this matter on November 26 through November 29, 2012. (D.I. 148-151.) Presently before the court are the parties' post-trial proposed findings of fact and conclusions of law concerning the validity of the patents-in-suit, specifically whether the asserted claims are invalid as obvious under 35 U.S.C. § 103. (D.I. 152, 153.) Pursuant to Federal Rule of Civil Procedure 52( a), and after having considered the entire record in this case and the applicable law, the court concludes that: (1) all asserted claims ofthe patents-in-suit are not invalid due to obviousness; and (2) Pfizer's Rule 52(c) motion is granted, and Mylan's Rule 52( c) motion is denied. These findings of fact and conclusions oflaw are set forth in further detail below. II. FINDINGS OF FACT 1 A. The Parties 1. Plaintiff Pfizer Inc.
    [Show full text]
  • Optimizing Binding Kinetics in Medicinal Chemistry: Facts Or Fantasy?
    Optimizing Binding Kinetics in Medicinal Chemistry: facts or fantasy? ‡ -Gon /RT kon e -G‡ /RT ‡ off ΔG on koff e -ΔGd/RT Kd e koff /kon P + L ‡ ΔG off ΔGd PL Gerhard Müller Ex-Head of Med Chem Mercachem, Nijmegen, NL Binding coordinate 11 The topic is hot, complex, and I am just an end-user & controversial “You can’t optimize koff, and you don’t need to optimize koff, you simply need to optimize Kd ! ” Head Med Chem, (top-5 Pharma), West Coast, US, Jan 2016 Optimizing Binding Kinetics in Medicinal Chemistry: facts or fantasy? ‡ -Gon /RT kon e -G‡ /RT ‡ off ΔG on koff e -ΔGd/RT Kd e koff /kon P + L ‡ ΔG off ΔGd PL Gerhard Müller Chief Scientific Officer Gotham Therapeutics, New YorkBinding coordinate 2 confidential Streetlight effect in medicinal chemistry Top-heavy distributions, rich-get-richer mechanisms 5% / 75% J. Med. Chem., 54 ,6405–6416 (2011) Vertex Pharmaceuticals, US J. Org. Chem. 73, 4443-4451 (2008) MW clogP shape clogP flatness Fsp3 flatland J. Med. Chem., 58, 2390−2405 (2015) para meta ortho J. Med. Chem., 59, 4443–4458 (2016) 3 Cheminformatics Analysis – Kinase Family Ligand and target promiscuity (ChEMBL21) Hu, Kunimoto, Bajorath Chemical Biology & Drug Design, 89, 834-845 (2017) quantitative kinome coverage 270 kinases with high-confidence data Top-10 kinases (45% of human kinome still unexplored) VEGFR2 TK 2239 erbB1 TK 1814 22.537 distinct IC50 values p38a CMGC 1509 9191 distinct scaffolds HGFR TK 1411 31.873 kinase-inhibitor combinations PI3a lipid 844 erbB-2 TK 768 GSK3b CMGC 743 SRC TK 709 Chk1 CAMK 693
    [Show full text]
  • SU14813: a Novel Multiple Receptor Tyrosine Kinase Inhibitor with Potent Antiangiogenic and Antitumor Activity
    1774 SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity Shem Patyna,1 A.Douglas Laird, 3 Dirk B.Mendel, 5 KIT, and FLT3. In cellular assays, SU14813inhibited ligand- Anne-Marie O’Farrell,2 Chris Liang,6 dependent and ligand-independent proliferation, migration, Huiping Guan,8 Tomas Vojkovsky,6 Stefan Vasile,7 and survival of endothelial cells and/or tumor cells express- B Xueyan Wang,9 Jeffrey Chen,1 Maren Grazzini,1 ing these targets. SU14813inhibited VEGFR-2, PDGFR- , Cheng Y.Yang, 10 Joshua O˝.Haznedar, 5 and FLT3phosphorylation in xenograft tumors in a dose- 4 1 and time-dependent fashion. The plasma concentration Juthamas Sukbuntherng, Wei-Zhu Zhong, in vivo 2 1 required for target inhibition was estimated to be Julie M.Cherrington, and Dana Hu-Lowe 100 to 200 ng/mL. Used as monotherapy, SU14813 1Pfizer Global Research and Development; 2Phenomix Corp., exhibited broad and potent antitumor activity resulting in San Diego, California; 3Exelixis, Inc.; 4Celera Genomics, Inc., regression, growth arrest, or substantially reduced South San Francisco, California; 5Chiron Corp., Emeryville, growth of various established xenografts derived from 6 7 California; The Scripps Research Institute; The Burnham human or rat tumor cell lines. Treatment in combination Institute, La Jolla, California; 8AstraZeneca PLC, Waltham, Massachusetts; 9Metabolex, Inc., Hayward, California; and with docetaxel significantly enhanced both the inhibition 10Gilead Sciences, Inc., Foster City, California of primary tumor growth and the survival of the tumor- bearing mice compared with administration of either agent alone. In summary, SU14813inhibited target RTK Abstract activity in vivo in association with reduction in angio- Receptor tyrosine kinases (RTK), such as vascular endo- genesis, target RTK-mediated proliferation, and survival thelial growth factor receptor (VEGFR), platelet-derived of tumor cells, leading to broad and potent antitumor growth factor receptor (PDGFR), stem cell factor receptor efficacy.
    [Show full text]
  • Documenting the Biotechnology Industry in the San Francisco Bay Area
    Documenting the Biotechnology Industry In the San Francisco Bay Area Robin L. Chandler Head, Archives and Special Collections UCSF Library and Center for Knowledge Management 1997 1 Table of Contents Project Goals……………………………………………………………………….p. 3 Participants Interviewed………………………………………………………….p. 4 I. Documenting Biotechnology in the San Francisco Bay Area……………..p. 5 The Emergence of An Industry Developments at the University of California since the mid-1970s Developments in Biotech Companies since mid-1970s Collaborations between Universities and Biotech Companies University Training Programs Preparing Students for Careers in the Biotechnology Industry II. Appraisal Guidelines for Records Generated by Scientists in the University and the Biotechnology Industry………………………. p. 33 Why Preserve the Records of Biotechnology? Research Records to Preserve Records Management at the University of California Records Keeping at Biotech Companies III. Collecting and Preserving Records in Biotechnology…………………….p. 48 Potential Users of Biotechnology Archives Approaches to Documenting the Field of Biotechnology Project Recommendations 2 Project Goals The University of California, San Francisco (UCSF) Library & Center for Knowledge Management and the Bancroft Library at the University of California, Berkeley (UCB) are collaborating in a year-long project beginning in December 1996 to document the impact of biotechnology in the Bay Area. The collaborative effort is focused upon the development of an archival collecting model for the field of biotechnology to acquire original papers, manuscripts and records from selected individuals, organizations and corporations as well as coordinating with the effort to capture oral history interviews with many biotechnology pioneers. This project combines the strengths of the existing UCSF Biotechnology Archives and the UCB Program in the History of the Biological Sciences and Biotechnology and will contribute to an overall picture of the growth and impact of biotechnology in the Bay Area.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0074497 A1 Schultz (43) Pub
    US 2005OO74497A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0074497 A1 Schultz (43) Pub. Date: Apr. 7, 2005 (54) HYDROGELS USED TO DELIVER Publication Classification MEDICAMENTS TO THE EYE FOR THE TREATMENT OF POSTERIOR SEGMENT (51) Int. Cl." ....................... A61K 39/395; A61K 38/24; DISEASES A61K 31/65; A61K 9/14; A61K 31/56; A61K 31/075 (76) Inventor: Clyde L. Schultz, Ponte Vedra, FL (52) U.S. Cl. ........... 424/486; 514/8; 514/12; 424/144.1; (US) 514/182; 514/721; 514/152 Correspondence Address: CLARK & ELBING LLP (57) ABSTRACT 101 FEDERAL STREET This invention provides a polymeric drug delivery System BOSTON, MA 02110 (US) including a hydrogel containing one or more drugs for the treatment of a posterior Segment disease. Exemplary drugs (21) Appl. No.: 10/971,997 are anti-angiogenesis compounds for the treatment of macu (22) Filed: Oct. 22, 2004 lar degeneration. Allowing passive transference of this drug from a dilute Solution into the hydrogel produces the deliv Related U.S. Application Data ery System. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is Sustained (63) Continuation-in-part of application No. 10/821,718, over an extended period of time, which is of particular utility filed on Apr. 9, 2004. in the eye, which is periodically flushed with tears. This Sustained delivery accelerates the treatment process while (60) Provisional application No. 60/461,354, filed on Apr. avoiding potential damaging effects of localized delivery of 9, 2003. high concentrations of compounds, e.g., from eye drops.
    [Show full text]
  • יומן הפטנטים והמדגמים Patents and Designs Journal
    י /' התשס"ח 5/2008 רשומות ISRAEL STATE RECORDS ו' באב התשס"ח August 7, 2008 יומן הפטנטים והמדגמים PATENTS AND DESIGNS JOURNAL פטנטים עמוד PATENTS Page בקשות שהוגשו Applications filed 1507 בקשות שקובלו Applications accepted 1775 פטנטים שניתנו Patents granted 1992 פטנטים שחודשו Patents renewed 1993 פטנטים שתוקפם פקעו Patents not in force 1995 פטנטים שחודשו לעשרים שנה Patents renewed for 20 years 1996 פטנטים שפג תוקפם Patents expired 1997 הודעות Notices 1998 שינויים בפרטים רשומים Changes in particulars entered בפנקס in register 2001 תיקוני טעויות Corrigenda 2002 מפתחות לבקשות שקובלו Indices of applications accepted i מדגמים DESIGNS מדגמים שנרשמו Designs registered 2004 מדגמים שחודשו Designs renewed 2017 מדגמים שבוטלו Designs void 2018 ו' באב התשס"ח – August 7, 2008 1507 ידיעות כלליות מכתבים, מסמכים, וכו' בענייני פטנטים ומדגמים יש לשלוח אל: רשם הפטנטים והמדגמים, רח' הסדנא 4, ירושלים לשכת הפטנטים נמצאת ברח' הסדנא 4, תלפיות, ירושלים והיא פתוחה לציבור בימי חול שאינם ערבי שבת או מועד בין השעות 8:30 ו - 12:30. לשכת הפטנטים מספקת תצלומים של פירוטים ושרטוטים במחיר של 2.50 שקלים בעד כל עמוד או חלק ממנו. אגרות ללשכת הפטנטים מתקבלות אך ורק על ידי תשלום לחשבון הלשכה בבנק הדואר מס' 0-24145-2. יש להציג קבלת בנק הדואר ללשכה יחד עם הבקשה לפעולה שעבורה האגרה שולמה. GENERAL INFORMATION Letters, documents, etc. concerning Patents and Designs should be addressed to: The Commissioner of Patents and Designs, 4 Hasadnah St., Jerusalem The Patent Office is located at 4 Hasadnah St., Talpiot, Jerusalem and is open to the public on weekdays, except on Fridays or on the eves of holydays, from 08:30 to 12:30 hrs.
    [Show full text]
  • Translating Academic Careers Into Industry Healthcare Professions
    careers & recruitment People Recent moves of note in and around the biotech and pharma industries. Janssen R&D has announced the Silverback Therapeutics has announced the appointment appointment of Najat Khan as chief data of Laura Shawver (photo) as president, CEO and member science officer. She was most recently the of the board of directors. She brings more than 25 years as company’s global head of strategy and a scientist, biotech leader and patient advocate to the role. operations in R&D, but will now also now Shawver was most recently CEO and director of Synthorx run the data science side, which aims to from 2017 until its acquisition by Sanofi in January for make R&D more efficient by mining data $2.5 billion. Previously, she was CEO and director of Cleave careers & recruitment in hopes of finding more pipeline winners Biosciences, entrepreneur-in-residence for 5AM Ventures, more readily. CEO and director of Phenomix, and president of Sugen. She is a director of Relay Therapeutics, as well as board chair of Cleave Therapeutics. Sangamo Therapeutics has named “With her range of strategic expertise, demonstrated success raising capital, scientific D. Mark McClung as executive vice acumen, and broad drug development experience, Laura is the perfect fit for Silverback,” president and chief business officer. said Peter Thompson, OrbiMed partner, cofounder and chairman of Silverback McClung was previously vice president Therapeutics. “I, along with Silverback’s entire board, look forward to working with and general manager of global oncology Laura and our exceptional leadership team to advance Silverback’s pipeline and deliver commercial at Amgen and, before on the promise to dramatically improve the lives of patients.” that, chief commercial officer at Onyx Pharmaceuticals.
    [Show full text]
  • Kinase Inhibitors Updated 02.09. 2020
    Reported Approved for Reported Approved for Reported Approved for Name Structure Company Name Structure Company Name Structure Company target clinical use target clinical use target clinical use 1995 cerebral ARRAY Fasudil (Eril) ROCK1/2 Asahi Kasei Trametinib MEK1/2 GSK 2013 skin cancer Binimetinib MEK RAF 2018 melanoma vasospasm PAH Novartis Sirolimus 1999 kidney 2013 NSCLC with Infinity mTOR Wyeth Pfizer Afatinib HER2 EGFR BI Duvelisib PI3K δ/ γ 2018 CLL SLL (Rapamune) transplantation EGFR mutations Verastem 2001 chronic Bruton's Bcr-Abl c- Janssen 2013 mantle cell 2018 NSCLC with Imatinib Novartis myelogenous Ibrutinib Tyrosine Dacomitinib EGFR Pfizer KIT PDGFR Pharmacyclic lymphoma, CLL EGFR mutations leukemia Kinase 2014 glaucoma 2018 acute Gefitinib EGFR AZ 2003 NSCLC Ripasudil ROCK Kowa Gilteritinib FLT3 AXL Astellas ocular hypertension myeloid leukemia Genetech 2004 NSCLC 2014 NSCLC with 2018 cancer with Erlotinib EGFR Ceritinib ALK Novartis Larotrectinib NTRK LOXO Bayer Roche pancreatic cancer ALK translocations NTRK fusions Multiple Gilead, 2014 chronic Tyrosine 2005 renal cancer Sorafenib Onyx Bayer Idelalisib PI3K δ Calistoga, lymphocytic Catequentinib VEGFRs Advenchen 2018 NSCLC kinases HCC ICOS leukemia, FL targeted Multiple 2006 renal cancer, VEGFR Tyrosine- 2014 idiopathic Sunitinib Sugen Pfizer Imatinib resistant Nintedanib PDGFR BI Lorlatinib ALK ROS Pfizer 2018 NSCLC kinases pulmonary fibrosis GIST FGFR targeted Multiple 2006 chronic Tyrosine- 2014 NSCLC with 2018 autoimmune Dasatinib BMS myelogenous Alectinib ALK
    [Show full text]
  • UR-Coeus Sponsor List
    UR-Coeus Sponsor Table (alphabetical by sponsor name) Sponsor Sponsor Code Sponsor Type 2138 21st Century Medicine CORP Sponsor Type Key 1 3M CORP CORP = Corporate 3803 4S3 Bioscience Inc CORP FED = Federal 5207 A. F. Associates Family Medicine ONFA FND = Foundation 2602 A. P. Pharma CORP IND = Individuals 2 A.L. Mailman Foundation FND NYS = New York State 2023 AA Implant Dentistry Research Foundation ONFA OLG = Other Local Gov't 3 AAA Fnd for Traffic Safety ONFA ONFA = Other Non-Fed Agency 2329 aaiPharma Inc CORP VHA = Voluntary Health Agency 3257 Aamjiwnaang First Nations Community ONFA 5345 Aarhus University Hospital ONFA 3713 Aaron Copland Fund for Music, Inc. ONFA 4 AARP Andrus Fdn FND 3853 AB Sciences CORP 3378 AB Vector, Inc CORP 899 Abbott Diagnostics CORP 3864 Abbott Fund FND 14 Abbott Laboratories CORP 5126 AbbVie, Inc. CORP 5854 Abeona Therapeutics CORP 5063 Abington Medical Specialists ONFA 5331 Abington Memorial Hospital ONFA 2835 ABIOMED, Inc. CORP 3687 Ablation Frontiers CORP 5118 Ablynx NV CORP 2053 ABMRF/Fnd for Alcohol Research ONFA 2171 Abortion Rights Mobilization ONFA 3361 Abraxix BioScience, LLC CORP 4953 Abt Associates, Inc. CORP 5037 Academic Gastrointestinal Cancer Consortium ONFA 15 Academic Med Ctr Cons ONFA 3733 Academic Pediatric Association ONFA 3160 Academy of Orofacial Pain ONFA 2122 Academy of Prosthodontics Foundation ONFA 3663 Acadia Pharmaceuticals, Inc. CORP 3273 Accelerate Brain Cancer Cure ONFA 5584 Acceleron Pharma Inc. CORP 5601 Accelovance, Inc. CORP 5940 Accreditation Council Grad Med Educ ONFA 5832 Accriva Diagnostics CORP 3888 AccuGenomics, Inc. CORP 5656 Acerta Pharma CORP 6101 Acessa Health, Inc.
    [Show full text]
  • Orphan Drug Designations and Approvals List As of 06‐02‐2014 Governs July 1, 2014 ‐ September 30, 2014
    Orphan Drug Designations and Approvals List as of 06‐02‐2014 Governs July 1, 2014 ‐ September 30, 2014 Row Designation Contact Generic Name Trade Name Designation Num Date Company/Sponsor (-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl- Novartis Pharmaceuticals 1 octahydro-indole-1-carboxylic acid methyl ester n/a 10/12/2011 Treatment of Fragile X syndrome Corp. (1-methyl-2-nitro-1H-imidazole-5-yl)methyl 2 N,N'-bis(2-broethyl) diamidophosphate n/a 6/5/2013 Treatment of pancreatic cancer EMD Serono (1-methyl-2-nitro-1H-imidazole-5-yl)methyl Threshold 3 N,N'-bis(2-bromoethyl) diamidophosphate n/a 3/9/2012 Treatment of soft tissue sarcoma Pharmaceuticals, Inc. Treatment of vaso-occlusive (1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O- crisis in patients with sickle cell 4 (sodium(2S)-3-cyclohexyl-propanoate- n/a 2/17/2009 disease. Pfizer, Inc. (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy- Treatment of acute Mundipharma Research 5 1,4-imino-D-ribitol-hydrochloride n/a 8/13/2004 lymphoblastic leukemia Limited (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy- Treatment of T-cell non- Mundipharma Research 6 1,4-imino-D-ribitol-hydrochloride n/a 1/29/2004 Hodgkin's lymphoma Limited Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T- (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy- cell leukemia, and hairy cell Mundipharma Research 7 1,4-imino-D-ribitol-hydrochloride n/a 8/10/2004 leukemia Ltd. (1S,3S)-3-amino-4- (difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4- difluoromethylenyl-1-cyclopentanoic acid Catalyst Pharmaceutical 8 hydrochloride n/a 9/15/2010 Treatment of infantile spasms.
    [Show full text]